AVRO News and Press, AVROBIO Inc. From 11/04/21

Provided comprehensive safety update on AVROBIO’s lentiviral gene therapy platform and programs at ESGCT 2021 Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial; registration study initiation anticipated for mid-2022 Cash ...

AVROBIO (NASDAQ:AVRO) announces that the U.S. FDA has granted Rare Pediatric Disease Designation to AVR-RD-05 for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys. The FDA&#x...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer. Dr. Ridha brings wide-ranging expertise in early- ...

AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene Therapy/Editing Summit at 10:30 a.m. ET...

No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will pres...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming virtual investor conferences. ...

The following slide deck was published by AVROBIO, Inc. in conjunction with this event. For further details see: Avrobio (AVRO) Investor Presentation - Slideshow